Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06068348 · ClinicalTrials.gov registry record
Liquid Biopsy Collection Study
A clinical trial of Circulating Tumor Cells and Chaperonin-Containing TCP-1, sponsored by University of Central Florida.
- Active
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06068348 is a study of Circulating Tumor Cells and Chaperonin-Containing TCP-1 that is active but no longer recruiting, run by University of Central Florida. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06068348, a study of Circulating Tumor Cells and Chaperonin-Containing TCP-1, is active but no longer recruiting, sponsored by University of Central Florida.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.
Conditions Studied
Study Locations (1)
Florida
- University of Central Florida - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2025-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06068348
The ClinicalTrials.gov registry entry for NCT06068348 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Circulating Tumor Cells appearing as the primary indexed condition, and to 0 interventions.
NCT06068348 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06068348 about?
NCT06068348 is a clinical study titled "Liquid Biopsy Collection Study". The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) ch...
What is the current status of trial NCT06068348?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2021-10-07. Estimated completion is 2025-10.
What conditions does trial NCT06068348 study?
This clinical trial studies the following conditions: Circulating Tumor Cells, Chaperonin-Containing TCP-1, CCT, CTC.
Who is sponsoring clinical trial NCT06068348?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06068348 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Circulating Tumor Cells
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.